Checkpoint Therapeutics I...

NASDAQ: CKPT · Real-Time Price · USD
4.26
0.00 (0.00%)
At close: May 29, 2025, 3:59 PM

Checkpoint Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
Period Ending Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Revenue
n/a n/a 47K 78K 68K 103K 171K 188K 175K 192K 134K 115K 252K 268K 279K 278K 165K
Cost of Revenue
17.46M 25.95M 21.28M 26.77M 36.24M 43.57M 49.5M 52.87M 50.98M 49.83M 63.25M 63.77M 58.91M 48.45M 29.4M 22.4M 18.23M
Gross Profit
8.5M n/a -21.23M -26.69M -36.17M -43.46M -49.33M -52.69M -50.81M -49.63M -63.11M -63.65M -58.66M -48.19M -29.12M -22.13M -18.07M
Operating Income
-56.38M -56.17M -37.51M -35.49M -45.01M -52.15M -58.62M -61.59M -59.55M -58.31M -71.43M -72.05M -67.04M -56.72M -37.2M -30.86M -26.38M
Interest Income
8K 11K 12K 17K 45K 84K 154K 199K 190K 160K 101K 62K 53K 53K 56K 57K 73K
Pretax Income
-56.51M -56.24M -46.47M -42.47M -52.32M -51.85M -53.74M -58.63M -56.25M -62.62M -71.36M -72.01M -67.01M -56.67M -37.14M -30.8M -26.3M
Net Income
-56.51M -56.24M -46.47M -42.47M -52.32M -44.24M -50.48M -55.26M -52.84M -66.79M -71.18M -71.94M -66.99M -56.67M -37.14M -30.8M -26.3M
Selling & General & Admin
24.97M 20.06M 9.92M 8.8M 8.84M 8.69M 9.29M 8.9M 8.75M 8.7M 8.35M 8.42M 8.41M 8.54M 8.53M 9.04M 8.61M
Research & Development
31.44M 36.15M 27.64M 26.77M 36.24M 43.57M 49.5M 52.87M 50.98M 49.83M 63.25M 63.77M 58.91M 48.45M 28.94M 22.1M 17.93M
Other Expenses
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Operating Expenses
56.42M 56.22M 37.56M 35.57M 45.08M 52.25M 58.79M 61.77M 59.73M 58.52M 71.59M 72.19M 67.32M 56.99M 37.47M 31.14M 26.54M
Interest Expense
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Selling & Marketing Expenses
n/a 100K 300K 300K 300K 200K 400K 400K 600K 600K 200K 200K n/a n/a n/a n/a n/a
Cost & Expenses
45.27M 56.22M 37.56M 35.57M 45.08M 52.25M 58.79M 61.77M 59.73M 58.52M 71.59M 72.19M 67.32M 56.99M 37.47M 31.14M 26.54M
Income Tax Expense
43.28K n/a -43.28K -43.28K -74.28K -7.64M -3.3M -3.4M -3.41M 4.17M -188K -138K -149.81K -179.02K -220.15K -166.15K -110.34K
Shares Outstanding (Basic)
598.24K 39.67M 43.15M 36.53M 32.93M 27.29M 19.99M 15.7M 11.75M 10.29M 8.86M 8.75M 8.5M 7.85M 7.85M 7.55M 7.03M
Shares Outstanding (Diluted)
598.24K 39.67M 43.15M 36.53M 32.93M 27.29M 19.99M 15.7M 11.75M 10.29M 8.86M 8.75M 8.5M 7.85M 7.85M 7.55M 7.03M
EPS (Basic)
-19.85 -1.44 -1.44 -1.5 -2.37 -2.28 -4.05 -4.95 -5.51 -7.25 -8.57 -8.81 -8.41 -7.36 -5.38 -4.82 -4.51
EPS (Diluted)
-19.85 -1.44 -1.44 -1.5 -2.37 -2.28 -4.05 -4.95 -5.51 -7.25 -8.57 -8.81 -8.41 -7.36 -5.38 -4.82 -4.51
EBITDA
-56.38M -56.17M -37.51M -35.49M -45.01M -52.15M -58.62M -61.59M -59.55M -58.33M -71.46M -72.07M -67.07M -56.72M -37.2M -30.86M -26.38M
EBIT
-45.3M -56.24M -37.51M -35.49M -45.01M -52.15M -58.62M -61.59M -59.55M -58.33M -71.46M -72.07M -67.07M -56.72M -37.2M -30.86M -26.38M
Depreciation & Amortization
-43.28K n/a 87.09K 7.79M 8.15M 535.81K 546.88K 3.51M 3.24M 27.67M 27.63M 17.02M 16.98M 179.02K 220.15K 218.9K 214.21K